Dementia and Perfect English

This post covers the topic of dementia, well-written English, and the effective use of money.
Dementia, English, and showing off wealth.
Bill Gates' father passed away from dementia, which led to significant support for research in this field, and this describes how dementia research is advancing. I highly recommend this to anyone looking to improve their English writing. I wonder if someone from a science background can write this well in terms of sentences, vocabulary, and structure. There is almost no difficult language, yet it reads seamlessly.
Personally, I enjoy these topics because I have family members—both my father and my in-laws—who were dementia patients.
Original: 8) Alzheimer’s tests and treatments are available right now | LinkedIn
Alzheimer’s tests and treatments are available right nowBut there are barriers that keep them from reaching everyone.
Ever since Alzheimer’s disease was first identified 120 years ago, it’s been associated with helplessness. It was hard to diagnose conclusively, and even if it was, there was nothing anyone could do about it. If a loved one had it—as my father did—you just had to watch them slowly disappear.
But thanks to recent scientific breakthroughs in diagnosing and treating Alzheimer’s, we’re not helpless anymore. I have been funding research on it since 2017, and although these new tools are not perfect, they are far and away the best news about this disease I have ever seen.
Now the field is running into a different challenge: The innovations aren’t reaching everyone who needs them. As I heard from a group of Alzheimer’s experts when we got together this past weekend, the scientific breakthroughs have outpaced the system designed to deliver them to doctors and patients. Fixing this problem is the next big frontier in Alzheimer’s.
The breakthroughs: a simple blood test for Alzheimer’s, and treatment if you need it.
It used to be that the only way to diagnose Alzheimer’s was with an expensive brain scan or spinal tap. That hurdle created a vicious cycle. Few people got tested because the procedure was so burdensome, and there was no treatment available anyway. Without large groups of people who were definitively diagnosed, researchers struggled to find patients who were eligible for clinical trials of tests and treatments. That inhibited the research that would lead to new tools, keeping the field largely stagnant for decades.
That is why the recent development of blood tests is such a big breakthrough. For the patient, the experience is the same as getting blood drawn to check your cholesterol. The first two blood tests came out last year, and the U.S. FDA just approved two new ones in August.
On treatment, the FDA has approved two antibody therapies that clear amyloid, the protein that is strongly associated with Alzheimer’s, and modestly slow cognitive decline. Both involve going to a clinic for an infusion, a process similar to the way cancer patients get chemotherapy.
The latest innovation happened just earlier this year: In July, the FDA approved a version that you can take at home with an injectable pen, the same thing that people use to take their GLP-1s. This makes it a lot more practical for patients, especially elderly people who are homebound or have limited mobility.
In the United States, Medicare even pays for the infusion treatment, making it more affordable for patients.
Why aren’t more people taking advantage of them?
The Alzheimer’s experts I met with over the weekend were in Seattle for a medical conference. When I asked them what uptake on these tools has been like, the consensus around the table was clear: It has been slow.
I was surprised to hear that, but not shocked. Most of my work is in global health, on diseases that disproportionately affect the poorest people in the world. Often—with vaccines, for example—there’s a solution that is widely available in high-income countries but unaffordable or impractical in low-income ones. A big part of the Gates Foundation’s mission is to close that delivery gap so everyone benefits from scientific innovations.
So what the Alzheimer’s specialists were telling me felt familiar. It’s not enough to make scientific breakthroughs; we also need breakthroughs in the systems that deliver them to patients. Here are some of the barriers we talked about:
Not everyone is aware. According to the experts I spoke with, many doctors and patients simply don’t know that these tests and treatments are available. It can take months to be approved for treatment. Primary care doctors are able to order the blood tests, but typically only memory specialists prescribe treatment. Since it can take months to get an appointment with a specialist, patients with a positive diagnosis often face a long wait before they can start their medication. That lost time is precious because the earlier you start treatment, the more effective it is. There are regulatory and bureaucratic obstacles. Most countries other than the U.S. don’t cover the blood tests in their health plans. Even in the U.S., whether Medicare will pay to test you depends on where you live. It doesn’t cover screening for cognitively healthy people at all. And patients have to pay much more out of pocket for the new injectable treatment than for the infusion. The infusion treatments are burdensome and have side effects. One of the drugs requires getting to an infusion clinic every two weeks for a year and a half, and then monthly after that. For a lot of patients, that is more than they can manage. In addition, the medicines can cause significant side effects in rare cases, so patients have to get a series of MRIs in the early stages of treatment. Clinical trials still struggle to find volunteers. To enroll, you have to live near a site where the trial is being run and be able to travel there. Researchers have an especially hard time recruiting diverse groups of participants, so they don’t understand the benefits of treatment equally across ethnic and racial groups.
What’s next?
I am thinking about how we can lower these barriers to delivery. Ultimately there should be an ecosystem of companies and providers working together. I don’t yet know what my role might be, but I am looking for ways to bring the right partners together to get things going.
One concrete thing that will accelerate progress is to get more people volunteering for clinical trials. The Alzheimer’s Association has an online tool that helps you learn whether you or a loved one is eligible and find an appropriate study if you are.
In the meantime, I am excited about the advances that are still to come. New blood tests are being developed that would detect tau, the protein that kills neurons and causes cognitive decline. New drugs could attack tau as well.
On the prevention side, published studies have already shown that diet, exercise, and social interactions can reduce the risk of cognitive decline; now researchers are studying whether treating people before they start showing symptoms will slow down the progression of the disease, delay its onset, or even prevent it altogether.
All of this work has implications for the entire world. Life spans are going up nearly everywhere, and people deserve to enjoy their golden years. I am optimistic that science will give us the tools to defeat Alzheimer’s. Let’s make sure those tools reach everyone who will need them.
---------------------
Auto-translation
Alzheimer’s tests and treatments are already available. However, barriers still exist in providing them to everyone.
Since Alzheimer’s disease was first identified 120 years ago, it has been seen as a symbol of helplessness and despair. It was difficult to diagnose conclusively, and even if diagnosed, there was nothing that could be done. When a loved one had Alzheimer’s, just as my father did, we could only watch as they slowly lost their memories and themselves.
But with recent scientific breakthroughs in the diagnosis and treatment of Alzheimer’s, we are no longer helpless. I have been funding Alzheimer’s research since 2017. Although the newly emerging tests and treatments are not perfect, I believe they are by far the most hopeful developments I have seen regarding this disease.
Now, this field is facing a new challenge: the fact that these innovative technologies and treatments are not reaching everyone who actually needs them. As I heard from Alzheimer’s experts I met with last weekend, the pace of scientific advancement has outstripped the pace of the medical systems that deliver them to doctors and patients. Solving this problem will be the next major task in the field of Alzheimer’s.
Breakthroughs: Simple blood tests and available treatments if needed.
In the past, diagnosing Alzheimer’s required expensive brain imaging or spinal fluid tests. This diagnostic process created a vicious cycle. Because the testing procedures were cumbersome, few people were tested, and since there were no treatments available anyway, there was little reason to undergo testing.
Due to the lack of a sufficient group of definitively diagnosed patients, researchers struggled to find suitable participants for clinical trials of new testing methods and treatments. This limited research for the development of new medical technologies, and as a result, the field of Alzheimer’s research failed to make significant progress for decades.
This is why the recently developed blood tests are such a major breakthrough. From a patient's perspective, the test can be performed in almost the same way as a blood draw to check cholesterol levels. The first two types of blood tests were released last year, and the U.S. Food and Drug Administration (FDA) approved two additional types in August this year.
There has also been great progress in the field of treatment. The FDA has approved two types of antibody therapies that remove amyloid, a protein closely associated with Alzheimer’s. These treatments somewhat slow the progression of cognitive decline.
Both treatments require visiting a hospital for administration via infusion. This is similar to the way cancer patients receive chemotherapy.
The most recent innovation occurred early this year. In July, an FDA-approved treatment in the form of a self-injectable pen that can be used at home was released. It is the same method used when people administer GLP-1 class drugs.
This method allows patients to receive treatment much more conveniently. It can be a great help, especially for elderly patients with limited mobility or those who have difficulty moving.
In the United States, Medicare covers the cost of infusion treatments, allowing patients to receive treatment more affordably.
Why are more people not taking advantage of these benefits?
The Alzheimer’s experts I met last weekend were attending a medical conference in Seattle. I asked them how much these new tests and treatments are actually being utilized in the field.
The experts' opinions were unanimous: the actual utilization rate is still low.
I was surprised by this answer, but on the other hand, I could fully understand it.
I mainly work in the field of global health, focusing on diseases that disproportionately affect low-income populations worldwide. In the case of many medical technologies, including vaccines, they are widely available in high-income countries but are often too expensive or impractical to use in low-income countries.
One of the important missions of the Bill & Melinda Gates Foundation is also to reduce this gap in medical service delivery so that everyone can benefit from scientific advancements.
That is why the stories shared by the Alzheimer’s specialists felt very familiar to me.
It is not enough to simply make scientific breakthroughs. We also need breakthroughs in the systems that deliver those innovative technologies and treatments to patients.
The main barriers we discussed are as follows:
1. Not everyone is aware of the new tests and treatments.
According to the experts I met, many doctors and patients do not even know that these tests and treatments are already available.
2. It can take months to get approval for treatment.
Primary care physicians can order blood tests, but typically only specialists, such as memory disorder specialists, can prescribe actual treatments.
Since it can take months to see a specialist, patients who receive a positive blood test result must wait a long time before they can start actual medication therapy.
Because treatment is more effective when started early, this delay robs patients of precious opportunities.
3. There are obstacles in regulation and administrative procedures.
Except for the United States, most countries do not yet support blood test costs through their health insurance systems.
Even in the U.S., whether Medicare covers the cost of testing depends on where you live. Screening for people with no cognitive issues is not covered at all.
Furthermore, the cost that patients must pay out-of-pocket for the new self-injectable treatment is much higher than for the infusion method.
4. Infusion treatments are cumbersome and have side effects.
One of the treatments requires visiting an infusion clinic every two weeks for the first year and a half, and then once a month thereafter.
This treatment schedule is an overwhelming burden for many patients.
Additionally, although rare, these drugs can cause serious side effects. Therefore, patients must undergo several MRI scans during the early stages of treatment.
5. It is still difficult to find volunteers for clinical trials.
To participate in a clinical trial, you must live near the medical institution where the trial is being conducted and be able to visit in person.
Researchers are having particular difficulty recruiting participants from diverse racial and ethnic backgrounds.
As a result, they are unable to fully understand how treatment effects vary across different racial and ethnic groups.
What should be done in the future?
I am thinking about ways to lower these barriers so that more people can receive new tests and treatments.
Ultimately, an ecosystem must be established where various companies and healthcare providers cooperate with one another.
While I am not yet certain what role I can play, I am looking for ways to bring necessary partners together to create practical change.
One concrete way to accelerate progress is to get more people to volunteer for clinical trials.
The Alzheimer's Association provides an online tool that helps you check if you or a family member is eligible to participate in a clinical trial and find an appropriate study.
Meanwhile, I have great expectations for the research results to come.
Currently, new blood tests are being developed to detect the tau protein. Tau is a protein that damages neurons and causes cognitive decline. New treatments that target and attack the tau protein are also being developed.
Promising research results are also emerging in the field of prevention.
Published studies have already shown that dietary habits, exercise, and social interaction can reduce the risk of cognitive decline.
Now, researchers are studying whether starting treatment before symptoms appear can slow the progression of the disease, delay its onset, or even prevent the disease itself.
All of this research and effort has significant implications for the entire world.
Life expectancy is increasing worldwide. Beyond simply living longer, people deserve to enjoy their golden years in health and happiness.
I am optimistic that science will provide us with the tools to overcome Alzheimer’s.
Now, what we must do is ensure that such tools and innovative treatments are delivered without exception to everyone who needs them.